Efficacy, safety and quality of life in patients receiving subcutaneous IgG treatment: experience in Bogotá, Colombia

Immunotherapy
María Claudia Ortega-LópezMónica León Pinilla

Abstract

Investigate efficacy, safety and quality of life of Gammanorm® 16.5% (subcutaneous immunoglobulin [SCIG]) in patients with primary immunodeficiencies (PIDs) and safety and to lesser extent efficacy in autoimmune diseases. Medical records were extracted from 31 pediatric and 12 adult patients who received SCIG as part of the Personalized Program at University Children's Hospital, Bogotá, Colombia. Mean SCIG dose was 28.7 g/month. Serious bacterial infections were observed in 7/33 patients in the PID group, most often bacterial pneumonia (3/33). There were no serious adverse events related to SCIG treatment. Drug-related adverse reactions were reported in 2/43 patients. Self-administration of SCIG provided effective protection, favorable tolerability and improved quality of life in patients with PIDs and autoimmune diseases from Colombia.

References

Oct 1, 1984·Annals of Internal Medicine·C Cunningham-RundlesR A Good
Sep 10, 2002·Clinical Immunology : the Official Journal of the Clinical Immunology Society·S HansenA Gardulf
Sep 19, 2003·The Journal of Allergy and Clinical Immunology·Stacey Radinsky, Vincent R Bonagura
Oct 14, 2004·The Journal of Allergy and Clinical Immunology·Ann GardulfMichael Borte
Jun 20, 2006·Journal of Clinical Immunology·Hans D OchsUNKNOWN Subcutaneous IgG Study Group
Oct 30, 2007·Clinical Immunology : the Official Journal of the Clinical Immunology Society·A GardulfUNKNOWN Vivaglobin Clinical Study Group
Oct 23, 2008·Immunology and Allergy Clinics of North America·Melvin Berger
Oct 23, 2008·Immunology and Allergy Clinics of North America·Malini V BholeHelen M Chapel
Dec 18, 2008·Journal of Clinical Immunology·Annarosa SoresinaUNKNOWN Italian Network for Primary Immunodeficiencies
Jul 11, 2012·Clinical and Experimental Immunology·J S OrangeB Grimbacher
Jan 15, 2014·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Stephen JollesRichard L Wasserman
May 30, 2014·Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology·William C GerthArthur S Zbrozek
Jul 2, 2016·Therapeutic Advances in Neurological Disorders·Verena I LeussinkMark Stettner
Aug 30, 2016·Revista colombiana de psiquiatría·Claudia Marcela VélezJavier H Eslava-Schmalbach
Sep 1, 2016·The Journal of Allergy and Clinical Immunology·Asbjørg Stray-PedersenJames R Lupski
Jun 2, 2017·Journal of the Neurological Sciences·Lars H Markvardsen, Thomas Harbo
Sep 14, 2017·International Journal of Preventive Medicine·Ana Carolina Amaya-AriasJavier H Eslava-Schmalbach
Dec 12, 2017·Journal of Clinical Immunology·Aziz BousfihaKathleen E Sullivan

❮ Previous
Next ❯

Citations

Dec 19, 2019·Immunological Medicine·Tomohiro MorioMikhail A Rojavin

❮ Previous
Next ❯

Software Mentioned

PedsQL

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.